Compare Adaptive Biotechnologies Corp (ADPT) vs FedEx Corporation (FDX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs FedEx Corporation — how do they compare? Adaptive Biotechnologies Corp trades at $20.25 (market cap $3.33B), while FedEx Corporation trades at $309.02 (market cap $74.66B). The key difference: FedEx Corporation is far larger — about 22.4× Adaptive Biotechnologies Corp's market cap, and FedEx Corporation pays a 1.56% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | FDX | |
|---|---|---|
Market Cap | $3.33B | $74.66B |
Sector | Health | Industrials |
52-Week High | $22.37 | $338.75 |
52-Week Low | $10.24 | $174.81 |
Enterprise Value | $3.19B | $108.67B |
Dividend Yield | — | 1.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
FedEx trades at $312.88, down slightly by 0.04% on the day, with a bearish technical signal from moving averages. Recent quarterly earnings have consistently beaten expectations, including Q1 2026 EPS of $6.31 versus $5.91 expected. The company is streamlining operations, highlighted by the sale of its supply chain unit to CMA CGM for $1.4 billion, while maintaining solid cash flow from operations of $7.04 billion in 2025.
The outlook is mixed: analyst consensus is bullish with a $365.73 price target, but margin recovery remains uncertain. Key risks include soft shipping demand and ongoing cost pressures. Upside potential hinges on successful execution of efficiency initiatives like DRIVE and Network 2.0 to expand profitability beyond current 4.88% net margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →
